StockData
Viatris Inc logo

Viatris Inc

VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/303% below fair value
$20.28−0.17 (-0.83%)

Close on Nov 18, 2026Market cap $23.29BP/E –Yield 2.37%

Viatris Products in Active Development by Year

Products in Active Development — Emerging Markets

Viatris Products in Active Development: 70 in FY2025, down 6.7% from a year earlier.

Latest, FY2025
70
Period ended Dec 31, 2025
Change on a year earlier
-6.7%
75 in FY2024
History
6 years
Since FY2020
Sources
3
Documents cited below

Where the FY2025 figure comes from

“Emerging Markets 95 75 ~70”

Source: Viatris 2025 Sustainability Report ↗

Reported in Viatris Sustainability Reports.

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedProducts in Active Development — Emerging MarketsYear on yearSource
FY2025Dec 31, 202570-6.7%Viatris 2025 Sustainability Report ↗
FY2024Dec 31, 202475-21.1%Viatris 2025 Sustainability Report ↗
FY2023Dec 31, 202395-5.0%Viatris 2025 Sustainability Report ↗
FY2022Dec 31, 2022100+42.9%Viatris 2024 Sustainability Report ↗
FY2021Dec 31, 202170-22.2%Viatris 2023 Sustainability Report ↗
FY2020Dec 31, 202090–Viatris 2023 Sustainability Report ↗

Cite this data

StockData. (2026). Viatris Products in Active Development, annual FY2020–FY2025 [Data set]. Compiled from Viatris SEC filings and investor materials. https://stockdatahq.com/stocks/vtrs/kpis/prod-dev-em

See every metric in the Viatris KPI table. Data updated Nov 16, 2026.

See a number that looks wrong?